Akebia Therapeutics, Inc. (AKBA) Stock Grade

About Akebia Therapeutics, Inc.'s fundamentals

Akebia Therapeutics is a biotechnology company with a market capitalization of $239.6 million that reported strong revenue growth of 47.5% year-over-year, though it operates at a net margin of -2.3% and posted a net loss in its latest annual statement. Despite operating losses, the company generated positive free cash flow, suggesting it is converting revenue into cash even as it invests heavily in operations. The company does not pay a dividend and cannot be evaluated on traditional profitability metrics like P/E ratio or return on equity due to its loss position.